Table 4.
Comparison of all lupus nephritis treatments for fertility issues (amenorrhea or ovarian failure)
| Treatment | Reference | OR (95 % CrI) | RR (95 % CrI) | RD % (95 % Crl) |
|---|---|---|---|---|
| CYC | PRED | 3.81 (1.26, 14.31) | 2.64 (1.18, 7.51) | 0.25 (0.04, 0.47) |
| MMF | 0.48 (0.09, 3.04) | 0.52 (0.11, 2.58) | −0.07 (−0.23, 0.13) | |
| AZA | 2.74 (0.26, 28.27) | 2.12 (0.30, 8.18) | 0.17 (−0.15, 0.65) | |
| CYC LD | 9.06 (0.63, 121.50) | 3.79 (0.68, 11.71) | 0.45 (−0.06, 0.81) | |
| MMF | CYC | 0.13 (0.03, 0.41) | 0.20 (0.05, 0.56) | −0.31 (−0.47, −0.16) |
| AZA | 0.69 (0.09, 5.08) | 0.79 (0.14, 1.95) | −0.08 (−0.37, 0.36) | |
| CYC LD | 2.23 (0.23, 23.20) | 1.46 (0.34, 2.71) | 0.19 (−0.27, 0.55) | |
| AZA | MMF | 5.25 (0.78, 54.39) | 3.68 (0.81, 19.08) | 0.22 (−0.02, 0.68) |
| CYC LD | 16.35 (1.97, 247.70) | 6.49 (1.72, 30.95) | 0.50 (0.06, 0.87) | |
| CYC LD | AZA | 3.20 (0.55, 21.24) | 1.69 (0.68, 6.12) | 0.22 (−0.11, 0.60) |
| Random-effects model | Residual deviance | 15.93 vs. 17 data points | ||
| Deviance information criteria | 72.233 | |||
| Fixed-effects model | Residual deviance | 16.16 vs. 17 data points | ||
| Deviance information criteria | 72.069 | |||
Based on eight RCTs with 839 patients: seven two-arm trials and one three-arm trial
Significant odds ratios are in italics
For absolute rates for events used for calculation of risk difference, please see Appendix 6
OR odds ratio, RR relative risk, RD risk difference, CrI credible interval, HD high dose, LD low dose; when not specified, it indicates standard dose, CYC cyclophosphamide, MMF mycophenolate mofetil, CSA cyclosporine, TAC tacrolimus, LEF leflunomide, PRED prednisone, prednisolone or methylprednisolone, AZA azathioprine, RTX rituximab
The odds ratios were transformed to relative risk (RR) and risk difference was done to allow ease for interpretation for clinicians and patients